Etiology and Clinical Features of Secondary Sclerosing Cholangitis: A Single-Center Retrospective Study From 2016 to 2024

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY

JGH Open Pub Date : 2025-02-21 DOI:10.1002/jgh3.70122

Xiangchen Meng, Jiafei Peng, Hongtao Wei

{"title":"Etiology and Clinical Features of Secondary Sclerosing Cholangitis: A Single-Center Retrospective Study From 2016 to 2024","authors":"Xiangchen Meng, Jiafei Peng, Hongtao Wei","doi":"10.1002/jgh3.70122","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Secondary sclerosing cholangitis (SSC) is a rare progressive biliary disease. We aimed to analyze the underlying causes, treatment approaches, and prognosis of SSC in order to enhance awareness of this disease.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective analysis was conducted on patients diagnosed with SSC in a single tertiary center in China between October 2016 and March 2024, focusing on the etiology, treatment modalities, and follow-up outcomes. Clinical outcomes were compared to patients with primary sclerosing cholangitis during the same period.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 21 patients were included in the study, with a median age of 42 (interquartile range 34, 57). The primary causes of SSC included surgical injury (seven cases, 33.3%) and drug-induction (six cases, 28.6%). Eight patients (38.1%) underwent ERCP, six patients (28.6%) received PTCD, and two patients (9.5%) underwent choledochoscopic bile duct dilation or stone extraction.Median follow-up time was 13 (interquartile range 10, 35) months, during which five patients (23.8%) died and five patients (23.8%) underwent liver transplants.Comparison of patients who received biliary decompression interventions and patients who did not revealed no significant difference in prognosis (<i>p</i> = 0.45). The median time of transplant-free survival was 35 months in the SSC group compared with 67 months in the PSC group. A trend toward a worse prognosis was observed in SSC compared to PSC (<i>p</i> = 0.13).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SSC is a complex disease with varied etiologies and poor prognosis, particularly when caused by bile duct surgical trauma. Bile duct decompression like ERCP does not offer long-term survival benefits. SSC exhibited a trend towards a less favorable prognosis compared to PSC.</p>\n </section>\n </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"9 2","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70122","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

Secondary sclerosing cholangitis (SSC) is a rare progressive biliary disease. We aimed to analyze the underlying causes, treatment approaches, and prognosis of SSC in order to enhance awareness of this disease.

Methods

A retrospective analysis was conducted on patients diagnosed with SSC in a single tertiary center in China between October 2016 and March 2024, focusing on the etiology, treatment modalities, and follow-up outcomes. Clinical outcomes were compared to patients with primary sclerosing cholangitis during the same period.

Results

A total of 21 patients were included in the study, with a median age of 42 (interquartile range 34, 57). The primary causes of SSC included surgical injury (seven cases, 33.3%) and drug-induction (six cases, 28.6%). Eight patients (38.1%) underwent ERCP, six patients (28.6%) received PTCD, and two patients (9.5%) underwent choledochoscopic bile duct dilation or stone extraction.Median follow-up time was 13 (interquartile range 10, 35) months, during which five patients (23.8%) died and five patients (23.8%) underwent liver transplants.Comparison of patients who received biliary decompression interventions and patients who did not revealed no significant difference in prognosis (p = 0.45). The median time of transplant-free survival was 35 months in the SSC group compared with 67 months in the PSC group. A trend toward a worse prognosis was observed in SSC compared to PSC (p = 0.13).

Conclusions

SSC is a complex disease with varied etiologies and poor prognosis, particularly when caused by bile duct surgical trauma. Bile duct decompression like ERCP does not offer long-term survival benefits. SSC exhibited a trend towards a less favorable prognosis compared to PSC.

Abstract Image